Products
Pertuzumab is commercially available as a concentrate for the preparation of an infusion solution (Perjeta). It was approved in many countries in 2012.
Structure and properties
Pertuzumab is a recombinant humanized IgG1 monoclonal antibody. It was developed as a successor to trastuzumab (Herceptin).
Effects
Pertuzumab (ATC L01XC13) has cytostatic and antiproliferative properties. The effects are based on binding to the extracellular dimerization domain (subdomain II) of the HER2 receptor. As a result, the antibody blocks dimerization with other members of the HER2 family, inhibiting intracellular signaling and leading to growth arrest and tumor cell death. Pertuzumab has a different binding site than trastuzumab, which binds to subdomain IV. Thus, synergistic effects are possible. The treatment allows for longer survival without further disease progression.
Indications
In combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic or locally recurrent breast cancer that cannot be surgically removed.
Dosage
According to the SmPC. Pertuzumab is administered as an intravenous infusion.
Contraindications
- Hypersensitivity
For complete precautions, see the drug label.
Interactions
No interactions with other drugs are known to date.
Adverse effects
The most common possible adverse effects include hair loss, skin rash, pruritus, digestive disturbances such as diarrhea and nausea, taste disturbances, decreased appetite, respiratory disturbances, fatigue, respiratory infections, mucosal inflammation, insomnia, neutropenia, anemia, leukopenia, neuropathy, headache, dizziness, and increased lacrimation.